XNASGRCL
Feb 21, Last price
10.25USD
Name
Gracell Biotechnologies Inc
Chart & Performance
Profile
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | |||||
Revenues | |||||
Cost of revenue | 624,658 | ||||
Unusual Expense (Income) | |||||
NOPBT | (624,658) | ||||
NOPBT Margin | |||||
Operating Taxes | 22 | ||||
Tax Rate | |||||
NOPAT | (624,680) | ||||
Net income | (607,509) 30.40% | ||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
Debt | |||||
Debt current | 129,989 | ||||
Long-term debt | 77,020 | ||||
Deferred revenue | |||||
Other long-term liabilities | 6,879 | ||||
Net debt | (1,251,195) | ||||
Cash flow | |||||
Cash from operating activities | (482,648) | ||||
CAPEX | (48,388) | ||||
Cash from investing activities | (48,332) | ||||
Cash from financing activities | 33,324 | ||||
FCF | (595,914) | ||||
Balance | |||||
Cash | 1,458,204 | ||||
Long term investments | |||||
Excess cash | 1,458,204 | ||||
Stockholders' equity | (1,551,530) | ||||
Invested Capital | 3,117,153 | ||||
ROIC | |||||
ROCE | |||||
EV | |||||
Common stock shares outstanding | 107,486 | ||||
Price | 0.46 -61.92% | ||||
Market cap | 49,444 -37.77% | ||||
EV | (1,201,751) | ||||
EBITDA | (547,150) | ||||
EV/EBITDA | 2.20 | ||||
Interest | 6,737 | ||||
Interest/NOPBT |